Triple Agonism Based Therapies for Obesity Current Cardiovascular Risk Reports Springer Nature Link GLP1 Receptor Agonist Mechanisms GLP1RAs mimic the effects of Human Glucagon Like Peptide1 (GLP1), 'fooling your body' into thinking you ingested more than you actually have, causing earlier onset fullness & eventual Glucagon Like Peptide 1 Based Therapies: A New Horizon in Obesity Management Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Identification and utility exploration of a highly potent and long acting bullfrog GLP 1 analogue in GLP 1 and amylin combination therapy ScienceDirect Glucagon like peptide 1 receptor: mechanisms and advances in therapy Signal Transduction and Targeted Therapy